ImpriMed provides a data-driven drug response prediction for pets with cancer. Their service helps veterinary oncologists personalize chemotherapy regimens by enabling a more informed decision for each patient’s cancer treatment. With 135+ veterinary oncology partners, ImpriMed has so far provided their precision medicine service to over 1,900 dogs with blood cancers. This enabled building an extensive dataset containing anything from cancer subcategories to the survivability of cancer cells to different chemotherapy drugs.
Through cancer research, big data analytics, and our AI-based predictive algorithms, ImpriMed can predict the most effective treatments for individual patients. Not only does the approach maximize the information useful for clinicians, but it also benefits patients by reducing the amount of time it takes to find the right chemotherapy.
